Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.
Packaging: airtight package for oversea shipment
Transportation: Ocean,Land,Air,Express
Supply Ability: 5000kgs monthly
Port: BEIJING,QINGDAO,SHANGHAI
E7080 is an oral multi-targeted tyrosine kinase (RTK) inhibitor. In addition to inhibiting RTK related to pro-angiogenesis and carcinogenic signaling pathways, it can also selectively inhibit vascular endothelium The kinase activity of growth factor (VEGF) receptors, including VEGF1, VEGF2, VEGF3, and FGFR, PDGFRα, KIT and RET. The drug was approved by the US FDA on February 13, 2015 for the treatment of locally recurring or metastatic, radioiodine refractory, and progressive differentiated thyroid cancer (DTC).
PRODUCT E7080
CAS 417716-92-8
MF C21H19ClN4O4
MW 426.85
Product Categories : API Intermediates > Lenvatinib Mesylate Intermediate
Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.
Fill in more information so that we can get in touch with you faster
Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.